Citadel Advisors
BIOS

Citadel Advisors’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Citadel Advisors’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-88,240
Closed -$871K – 14533
2022
Q1 		$871K Buy
+88,240
New +$871K ﹤0.01% 8018

Other funds holding BIOS

Saba Capital Management
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Polar Asset Management Partners
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Cantor Fitzgerald
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
AQR Arbitrage
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Citadel Advisors's BIOS Position: Q2 2022 in Review

Citadel Advisors sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q2 2022, closing a stake of 88,240 shares — an estimated $871K sold.

Citadel Advisors first reported a position in BIOS in Q1 2022 and held it in 1 quarter. The position peaked at $871K in Q1 2022. 65 funds tracked by Wall St. Rank hold BIOS as of Q2 2022.

  • Citadel Advisors reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 88,240 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q2 2022, an estimated $871K.
  • Citadel Advisors first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 1 quarter.
  • Citadel Advisors's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $871K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.